Atossa Therapeutics (ATOS) announced a research collaboration with Nona Biosciences, a global biotechnology company providing integrated solutions from target validation and antibody discovery through preclinical research. The collaboration leverages Nona’s proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidates for breast cancer eliminating the need for additional engineering or humanization. To date, Harbour Mice platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress
- Strategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics
- Atossa Therapeutics Reports 2024 Financial Results and Updates
- Atossa Therapeutics reports Q4 EPS (20c), consensus (22c)
- Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating